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ABSTRACT
Introduction To examine how the risk of cardiovascular 
disease changes according to degree of change in body 
mass index (BMI) and low- density lipoprotein (LDL)- 
cholesterol in patients with diabetes using the health 
medical examination cohort database of the National 
Health Insurance Service in Korea. In comparison, the 
pattern in a non- diabetic control group was also examined.
Research design and methods The study samples 
were 13 800 patients with type 2 diabetes and 185 898 
non- diabetic controls, and their baseline characteristics 
and repeatedly measured BMI and LDL- cholesterol until 
occurrence of cardiovascular disease were collected in 
longitudinal data. We used the variability model that is joint 
of mixed effects and regression model, then estimated 
parameters about variability by Bayesian methods.
Results The risk of cardiovascular disease was increased 
significantly with high average real variability (ARV) of BMI 
in the patients with diabetes, but the risk of cardiovascular 
disease was not increased according to degree of ARV in 
non- diabetic controls. The Bayesian variability model was 
used to analyze the effects of BMI and LDL- cholesterol 
change pattern on development of cardiovascular disease 
in diabetics, showing that variability did not have a 
statistically significant effect on cardiovascular disease. 
This shows the danger of the former simple method when 
interpreting only the mean of the absolute value of the 
variation.
Conclusions The approach of simple SD in previous 
studies for estimation of individual variability does not 
consider the order of observation. However, the Bayesian 
method used in this study allows for flexible modeling 
by superimposing volatility assessments on multistage 
models.
INTRODUCTION
Cardiovascular disease is one of the major 
causes of death in Korea,1 and to reduce 
the incidence of cardiovascular disease, it is 
very important to know your risk factors and 
to prevent and/or manage them well. The 
concept of risk factors for cardiovascular 
disease began with the Framingham study in 
the 1960s, which noted factors of age, sex, 
family history, smoking, hypertension, hyper-
lipidemia, insulin resistance and diabetes, 
lack of exercise, and obesity.2 It is not clear 
whether obesity alone increases the risk of 
cardiovascular disease or whether the risk 
is increased by interaction of other factors 
related to obesity. Traditionally, however, 
some studies have reported that independent 
obesity may be linked to future cardiovascular 
disease.3 Treatments that lower low- density 
lipoprotein (LDL)- cholesterol reduce the risk 
of coronary artery disease, and several studies 
have shown that a 20%–60% reduction in 
LDL- cholesterol with statins reduces about 
34% of coronary events over a 5- year period 
Significance of this study
What is already known about this subject?
 ► Risk factors for cardiovascular disease are age, sex, 
smoking, diabetes, and obesity, and lifestyle man-
agement is important to reduce the incidence of car-
diovascular disease.
 ► In particular, weight changes in diabetics are close-
ly related to cardiovascular disease, and there are 
several studies showing that risk of cardiovascular 
disease changes according to increase or decrease 
of cholesterol level.
What are the new findings?
 ► In patients with diabetes, OR in the group with high 
body mass index (BMI) variability was 1.51 (95% 
CI 1.04 to 2.20), which significantly increased the 
risk of cardiovascular disease compared with the 
group with low variability. However, fluctuations in 
BMI did not affect incidence of cardiovascular dis-
ease with Bayesian variability model ( vBMI =−0.05, 
p=0.273).
 ► The risk of cardiovascular disease did not increase 
according to variability of low- density lipoprotein- 
cholesterol in both average real variability and 
Bayesian variability model.
How might these results change the focus of 
research or clinical practice?
 ► A simple method to use the variability created by 
calculating statistics as a risk factor can produce 
false results.
 ► Depending on the nature of the repeated mea-
sures data, the analysis method should be carefully 
selected.
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compared with placebo.4 In addition, patients with type 
2 diabetes may experience reduced risk of cardiovas-
cular disease when high high- density lipoprotein (HDL)- 
cholesterol level is maintained.5
Diabetes is a major risk factor for cardiovascular disease 
according to the American Heart Association, which 
emphasizes management of lifestyles for diabetics.6 
Obesity and cholesterol are important indicators of life-
style. Insulin resistance caused by diabetes can reduce 
HDL- cholesterol and triglyceride levels, which are indic-
ative of hyperlipidemia, and consequently increase the 
risk of cardiovascular disease. In addition, patients with 
diabetes are often mildly obese, and use of regular diabetes 
medications except metformin contributes to weight 
gain.7 A study in the USA found that weight increased 
after the onset of diabetes, and weight control efforts 
were an important factor in diabetes management.8
In particular, a study on the effects of weight loss on 
cardiovascular disease risk in overweight and obese 
patients with diabetes showed that the risk of cardiovas-
cular disease was significantly reduced by losing 5%–10% 
of body weight within 1 year.9 However, a Korean study 
found that overall risk of death and cardiovascular 
mortality in the increased weight group was lower than 
in the maintenance group.10 There is controversy over 
the relationship between development of cardiovascular 
disease and changes in weight and body mass index 
(BMI) in people with diabetes compared with the normal 
population.
The medical examination of the National Health Insur-
ance Service (NHIS) in Korea is performed in adults and 
includes measurement of BMI, blood pressure, choles-
terol, diabetes, hypertension, smoking, and exercise, all 
of which affect cardiovascular disease. Thus, analysis of 
these periodic and cumulative data may play an important 
role in predicting cardiovascular disease occurrence. If 
values such as BMI and cholesterol are high, or if their 
variabilities are rapid, we will be able to provide evidence 
as to whether they can affect the occurrence of cardiovas-
cular disease.
There are some points to be aware of when observing 
variability in repeated measures data. In longitudinal 
data, the period of measurement should be consid-
ered. For example, blood pressure is high during the 
day and low at night. Therefore, if the blood pressure 
is repeatedly measured every day or night, it can be 
regarded as a short- term fluctuation. And since medical 
examination conducted by NHIS is taken every year or 
every 2 years, blood pressure measured at that time is a 
long- term change. The visit- to- visit variability refers to 
the degree of change in the value observed each time a 
patient visits a medical institution, which is also a long- 
term variation. In addition, it is necessary to examine 
whether the interval of repeated measurement points is 
constant or not. The number of time points for analysis 
is also important, but there are no guidelines on how 
the results of the estimates vary with the number of time 
points used.
The purpose of this study is to identify the pattern of 
changes in BMI and LDL- cholesterol by occurrence of 
disease in Korean patients with diabetes and the effect 
of variability of the two indicators on development of 
cardiovascular disease. In addition, we examined how 
biomarker change patterns affect cardiovascular disease 
in normal adults.
RESEARCH DESIGN AND METHODS
Data and subject selection
In this study, we used the NHIS- Health Screening to 
analyze the effects of BMI and LDL- cholesterol change 
patterns on cardiovascular disease. This database is a 
cohort form of claims for medical information. The 
sample is randomly selected from 10% of all Koreans 
aged 40–80 years who had medical examination in 2002–
2003. The sample size is 514 795 and includes informa-
tion on health insurance, income, medical history, health 
medical examination results, and medical institutions in 
2002–2015.
The patients with diabetes in this study were diagnosed 
with type 2 diabetes mellitus prior to 2003 and were 
defined operationally based on the International Clas-
sification of Diseases 10th Revision codes and diabetes- 
related medication.11 12 Patients who were non- diabetic 
had no diabetes- related medication use and fasting blood 
sugar <126 mg/dL in health check- ups. Both groups 
excluded subjects with diseases such as cancer, hyperthy-
roidism, hypothyroidism, liver cirrhosis, and renal failure 
that could affect changes in BMI and LDL- cholesterol. 
The exclusion of subjects is 4169 in diabetic and 28 300 in 
non- diabetic controls, and some of them had more than 
one disease, so it was expressed as the total number of 
patients. Cardiovascular disease was defined as hospital-
ization for cardiovascular disease, more than four outpa-
tient visits per year, or death within 30 days of the first 
diagnosis. To secure the observation period for disease 
occurrence, cardiovascular patients before 2004 were 
excluded from the study. The final subjects were 13 800 
patients with diabetes and 185 898 non- diabetic controls 
(figure 1). Among them, the rate of new cardiovascular 
Figure 1 Selection of study subjects.
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disease in 2005–2015 was 27.7% and 6.4%, respectively, 
averaging 2.9% and 0.6% each year.
The selected subjects were followed to 2015 to deter-
mine the associations between repeated measures of 
biomarker changes and development of cardiovascular 
disease.
Statistical method
Since timing of cardiovascular disease occurrence and 
repeated examinations differ from subject to subject, 
an analysis considering this is essential. Using longitu-
dinal data, changes in BMI and cholesterol are affected 
by previous conditions, and the relationships between 
confounders and exposure variables should be included 
in the analysis.
There are several methodologies where time- 
dependent covariates are included in the analysis of risk 
factors that affect occurrence of an event. In the tradi-
tional Cox regression model, if the baseline risk factors 
are long- term effect and change over time, individual 
time windows can be defined to calculate the risk and 
estimate weighted average of overall risk.13 This model is 
also widely used to assume a marginal structural model 
that homogenizes the distribution of confusion factors 
between exposure and disturbance variables at each time 
point using inverse probability of treatment weighting.14 
In addition, a two- stage method using mixed effects 
model and time- to- event model and joint modeling are 
possible to estimate parameters. The methods described 
above do not include direct interpretation of the degree 
to which time- dependent covariates change over time. 
For example, a high cholesterol group measured repeat-
edly may show a higher risk of developing cardiovascular 
disease, but additional analysis is needed regarding risk 
of high cholesterol changes until the onset of cardiovas-
cular disease.
In this study, we consider the concept of intraindividual 
variation as a repeated measure from baseline to event 
occurrence. When variability is treated as a predictor in a 
model, it is usually used to quantify individual SD (ISD), 
coefficient of variation, or root mean square of succes-
sive differences, which are simple but can provide biased 
results due to integration of linear effects over time.15 
The Bayesian variability model was fitted including esti-
mates of individual variability.
The Bayesian variability model is largely divided into two 
parts. First, intraindividual variation is modeled and esti-
mated to explain measurement error, and then a predic-
tion model including the estimated value is constructed. 
Let Y be the outcome and V be the within- person variable 
that includes repeated measures. The purpose of estima-
tion is to predict the score for Y using intraindividual vari-
ation at V and, if possible, to estimate the mean of each 
individual in V with an additional predictor of Y.
If N individuals each have an individual mean  µj  and an 
ISD  σj , then the distribution of V is expressed as




, i = 1, 2, . . . , Ij , j = 1, 2, · · · , N 





where  σj  is a gamma distribution with scale and shape 
parameters α and β. After estimating the ISD, we can fit it 
into a standard linear regression as a predictor of Y:





 µ2j = β1 + · · ·+ βkCovariatek + α1σj + α2µj 
Two parameter vectors for latent  σj  and  µj  are related to 
intraindividual variability. The Bayesian variability model 
can be estimated using Markov chain Monte Carlo.
RESULTS
Subject characteristics
To determine the overall pattern of changes in BMI and 
LDL- cholesterol in diabetic and non- diabetic controls, 
the mean and SE of the time point before the onset 
date of cardiovascular disease or the end of the study 
(December 2015) were calculated as shown in figure 2. 
As the results are compiled from yearly health medical 
examinations before the index date, the number of 
samples fluctuates because there are examinees who did 
not receive medical examination at each point. Although 
the rate of missing at each point is high based on the total 
number of subjects, it is not unreasonable to examine the 
approximate pattern since it is a missing at random. In 
the database of NHIS, BMI has been included since 2002 
and LDL- cholesterol since 2009, so the number of time 
points is different. In the early 2000s, the SE at each time 
point was large due to the low examination rate. BMI 
and LDL- cholesterol levels in patients with diabetes tend 
to decrease gradually with approach to the index date, 
but general variability is greater in patients with cardio-
vascular disease. In addition, BMI and LDL- cholesterol 
of the non- diabetic control group showed similar values 
at each time point, although variability in cardiovascular 
disease was slightly larger.
To observe the variability of repeatedly measured 
biomarkers, we selected subjects who underwent three 
or more total health check- ups before onset of cardio-
vascular disease or the end of the study. In other words, 
Figure 2 Change patterns of body mass index (BMI) 
and low- density lipoprotein (LDL)- cholesterol. CVD, 
cardiovascular disease.
4 BMJ Open Diab Res Care 2020;8:e001340. doi:10.1136/bmjdrc-2020-001340
Cardiovascular and metabolic risk
occurrence of cardiovascular disease may be observed 
after at least 2007, but selection bias may exist. However, 
analysis of biomarker variability before the index date is 
the main purpose of this study, and this can be excluded. 
Three or more check- ups were performed by 996 patients 
with diabetes and 27 654 non- diabetic controls, respec-
tively, and 164 and 952 people had cardiovascular disease.
Table 1 shows the general characteristics of the study 
subjects; since the majority of examinees over 40 who 
receive regular health check- ups are employed, there was 
a higher proportion of men in the study subjects. There 
was a difference in distribution of age group between 
patients with cardiovascular disease and those with non- 
cardiovascular disease, and the proportion of patients 
with cardiovascular disease over 50 was higher. Smoking 
and exercise items had some missing data from the ques-
tionnaire. In both diabetic and non- diabetic controls, the 
rate of smoking was higher and there was a tendency to 
exercise less in patients with cardiovascular disease. In 
addition, BMI and LDL- cholesterol at baseline did not 
differ depending on the occurrence of cardiovascular 
disease in diabetic controls, but in non- diabetic controls, 
patients with cardiovascular disease had higher BMI.
Changes in BMI and LDL-cholesterol and cardiovascular 
disease
First, it was confirmed whether cardiovascular disease 
occurred according to degree of variability of biomarkers 
by multivariate logistic regression model (table 2). 
Average real variability (ARV) of BMI and LDL- cholesterol 
was calculated and classified into low and high groups 
based on median. The median ARV of BMI was 0.57 in 
patients with diabetes and 0.55 in non- diabetic controls. 
The median ARV of LDL- cholesterol was 18 and 17, 
respectively.
In patients with diabetes, OR in the group with high 
BMI variability was 1.51 (95% CI 1.04 to 2.20), which 
significantly increased the risk of cardiovascular disease 
compared with the group with low variability. However, in 
non- diabetic controls, the risk of cardiovascular disease 
did not increase according to degree of change. OR of 
the high LDL- cholesterol variability was 1.37 (95% CI 
Table 1 Characteristics of study subject








(n=26 702) P value
Sex
  Female 23 (14.0) 138 (16.6) 0.4153 191 (20.1) 7747 (29.0) <0.0001
  Male 141 (86.0) 694 (83.4) 761 (79.9) 18 955 (71.0)
Age
  40–49 82 (50.0) 554 (66.6) <0.0001 688 (72.3) 24 841 (85.5) <0.0001
  50–59 65 (39.6) 247 (29.7) 232 (24.4) 3537 (13.2)
  60+ 17 (10.4) 31 (3.7) 32 (3.4) 324 (1.2)
Smoking
  No 98 (64.1) 624 (75.0) 0.0049 645 (70.8) 20 833 (78.2) <0.0001
  Yes 55 (35.9) 208 (25.0) 266 (29.2) 5806 (21.8)
  Missing 11 41 63
Exercise
  No or light 36 (22.2) 136 (16.3) <0.0001 263 (27.9) 4512 (16.9) <0.0001
  Moderate 88 (54.3) 325 (39.1) 464 (49.2) 12 582 (47.1)
  Hard 38 (23.5) 371 (44.6) 216 (22.9) 9602 (36.0)
  Missing 2 9 6
SBP 128.2 (13.9) 126.3 (13.6) 0.1065 127.4 (14.9) 122.8 (13.5) <0.0001
Total cholesterol 192.7 (37.8) 179.1 (35.9) <0.0001 199.2 (35.2) 201.0 (34.1) 0.0965
BMI 24.5 (2.8) 24.2 (2.6) 0.1251 24.2 (2.8) 23.7 (2.7) <0.0001
LDL- cholesterol 103.8 (24.7) 100.4 932.5) 0.3022 118.2 (33.4) 121.0 (32.2) 0.0483
ARV of BMI 0.8 (0.7) 0.7 (0.5) 0.0109 0.7 (0.5) 0.7 (0.5) 0.3296
ARV of LDL- cholesterol 28.7 (37.6) 21.7 (15.1) 0.1457 22.0 (14.7) 20.9 (19.8) 0.0840
n (%) or mean (SD).
The p value is for testing the difference in distribution of characteristics of CVD and non- CVD in each group. It is desirable to interpret the 
significance level of statistical decision- making down to 2.5% by Bonferroni’s correction to control family- wise type 1 error rate.
ARV, average real variability; BMI, body mass index; CVD, cardiovascular disease; LDL, low- density lipoprotein; SBP, systolic blood pressure.
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0.80 to 2.34) and 1.35 (95% CI 1.13 to 1.61) in diabetic 
and non- diabetic controls, respectively. It suggests that 
risk of cardiovascular disease increased in non- diabetic 
controls. In addition, as is generally known, non- smoking 
and exercise may reduce the incidence of cardiovascular 
disease. When the BMI was adjusted in diabetic controls, 
the OR is 1.56 (95% CI 1.04 to 2.34) for smoking and 
0.35 (95% CI 0.21 to 0.59) for high- intensity exercise. 
In non- diabetic controls, the OR is 1.41 (95% CI 1.21 
to 1.65) for smoking and 0.38 (95% CI 0.31 to 0.46) for 
high- intensity exercise.
The results of the Bayesian variability model of patients 
with diabetes are shown in table 3. The intercept of BMI 
indicates that the average BMI is about 24. There was 
an individual difference in mean BMI ( σµ =2.50), and 
the variability among individuals was estimated to be 
7.89/9.58=0.82. However, fluctuations in BMI did not 
affect incidence of cardiovascular disease ( vBMI =−0.05, 
p=0.273). LDL- cholesterol in patients with diabetes was 
about 101 mg/dL, and there was an individual difference 
in mean LDL- cholesterol, with an estimated 23.33 indi-
vidual variability. As with BMI, change in LDL- cholesterol 
did not have a statistically significant effect on cardiovas-
cular disease. Similar to the results above for ARV, the 
significant factors affecting development of cardiovas-
cular disease were age, smoking, and exercise.
DISCUSSION
The relationships between cardiovascular disease, 
obesity, exercise, and nutrition have been studied in 
the academic community. As a result, a healthy life with 
monotonous reductions in weight and LDL- cholesterol 
has been shown to help lower cardiovascular disease. 
However, in diabetics who have difficulty managing 
weight long term, and in whom weight fluctuations are 
frequent, it is necessary to understand the effect of this 
fluctuation on cardiovascular disease.
Patients with diabetes with high ARV in BMI are 
thought to have a significantly higher risk of cardiovas-
cular disease, though this is not shown in the Bayesian 
variability model. This shows the danger of the former 
simple method when interpreting only the mean of the 
absolute value of the variation. The majority of vola-
tility studies only care about the degree of variation and 
do not consider the timing. The purpose of this study 
was to reduce the error of interpretation by applying a 
model that reflects the time point of measured values. As 
an alternative, a Bayesian variability model was applied. 
In this model, ISDs are distributed, allowing estima-
tion of type of variation. Application of such a model 
requires assumptions and technical considerations. Many 
methods of analyzing the impact of variability on events 
of interest have not been developed yet. It is considered 
Table 2 The effect of variability level on CVD incidence
Diabetic control Non- diabetic control
BMI LDL- cholesterol BMI LDL- cholesterol
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Sex
  Female 1.00 1.00 1.00 1.00
  Male 1.52 (0.86 to 2.67) 1.10 (0.52 to 2.31) 1.30 (1.09 to 1.56) 1.31 (1.04 to 1.65)
Age
  40–49 1.00 1.00 1.00 1.00
  50–59 2.28 (1.54 to 3.37) 1.67 (0.96 to 2.91) 2.15 (1.83 to 2.53) 1.84 (1.49 to 2.28)
  60+ 4.93 (2.36 to 10.30) 2.33 (0.75 to 7.19) 3.46 (2.36 to 5.07) 3.25 (2.03 to 5.20)
Smoking
  No 1.00 1.00 1.00 1.00
  Yes 1.56 (1.04 to 2.34) 1.12 (0.61 to 2.06) 1.41 (1.21 to 1.65) 1.38 (1.13 to 1.69)
Exercise
  No or light 1.00 1.00 1.00 1.00
  Moderate 1.05 (0.65 to 1.69) 1.10 (0.52 to 2.33) 0.66 (0.56 to 0.77) 0.89 (0.70 to 1.12)
  Hard 0.35 (0.21 to 0.59) 0.85 (0.40 to 1.79) 0.38 (0.31 to 0.46) 0.78 (0.61 to 1.00)
Variability
  Low 1.00 1.00 1.00 1.00
  High 1.51 (1.04 to 2.20) 1.37 (0.80 to 2.34) 0.93 (0.81 to 1.06) 1.35 (1.13 to 1.61)
SBP 1.00 (0.99 to 1.02) 1.01 (0.99 to 1.03) 1.02 (1.01 to 1.02) 1.02 (1.01 to 1.02)
Total cholesterol 1.01 (1.01 to 1.02) 1.01 (1.00 to 1.02) 1.00 (0.99 to 1.00) 1.00 (0.99 to 1.00)
BMI or LDL- cholesterol 1.05 (0.98 to 1.13) 1.00 (0.98 to 1.01) 1.07 (1.04 to 1.10) 1.00 (1.00 to 1.01)
BMI, body mass index; CVD, cardiovascular disease; LDL, low- density lipoprotein; SBP, systolic blood pressure.
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that a sensitivity analysis for the application of models is 
necessary.
For LDL- cholesterol, the estimation results of ARV 
and Bayesian variability models did not show a statisti-
cally significant effect on cardiovascular disease. It is not 
necessary to pay attention yet to the rapid fluctuation of 
LDL- cholesterol. Maintaining an adequate level of LDL- 
cholesterol may help prevent cardiovascular disease. 
Common factors affecting cardiovascular disease were 
age, smoking, and exercise, in line with other cardiovas-
cular research. The incidence of cardiovascular disease 
increases in the elderly and smokers, and high- intensity 
exercise may lower the incidence of cardiovascular 
disease. This is true for both diabetic and non- diabetic 
controls.
CONCLUSION
An approach such as ISD for estimating individual vari-
ability does not consider the order of observation. The 
Bayesian method used in this study allows for flexible 
modeling of trends by applying variability assessments to 
multistage models and shows how to apply individual vola-
tility as a predictor. Fitting the Bayesian variability model 
for patients with diabetes, we have not found evidence 
that sudden variability in BMI and LDL- cholesterol may 
affect the development of cardiovascular disease.
The following limitations exist in this study. Due to the 
characteristics of the health screening, they are measured 
every year, and the intervals between the measured points 
are too long to conduct the variability of the values. Since 
the number of measurements is small, from a minimum 
of 3 to a maximum of 11, there is a possibility of unstable 
estimation, and the state of glycemic control, duration of 
disease, and drug change. In addition, the Bayesian vari-
ability model does not include a complex model of time 
dependency considering only volatility. Despite these 
limitations, this study presented an analytical method 
using variability as a predictor.
There is no detailed guidance on the number of samples 
or repeated measurements required when applying the 
Bayesian variability model. It is necessary to consider the 
allowed magnitude of variability in model estimation. In 
addition, discussion of the extended concept of the vola-
tility model as a discontinuous and non- normal distribu-
tion is left for further study.
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